ARVN Stock Risk & Deep Value Analysis
Arvinas Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ARVN Stock
We analyzed Arvinas Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARVN through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ARVN Risk Analysis & Red Flags
What Could Go Wrong
The company faces a significant risk if it fails to secure a favorable new partnership for its lead asset, vepdegestrant (ARV-471), by the early June PDUFA. This, combined with the severe lack of available financial data, creates substantial uncertainty regarding its funding runway and ability to independently advance its costly clinical pipeline, potentially leading to significant share dilution or a material slowdown in development.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Seeking new vepdegestrant partner for lead asset (ARV-471), indicating uncertainty with previous Pfizer partnership.
- ⚠
Severe lack of publicly available fundamental financial data (earnings, cash flow, balance sheet).
- ⚠
Vanguard's reported 0% ownership due to internal realignment, a notable institutional exit.
- ⚠
ARV-806 (KRAS G12D) targets a 'highly competitive area' in oncology.
Upcoming Risk Events
- 📅
Failure to secure a favorable new vepdegestrant partner by early June PDUFA
- 📅
Negative or inconclusive clinical trial data for ARV-471, ARV-806, or ARV-393
- 📅
Increased cash burn without securing new funding or clear path to profitability
When to Reconsider
- 🚪
Failure to announce a new vepdegestrant partnership by PDUFA date or an unfavorable partnership deal.
- 🚪
Major clinical trial failure for ARV-806 or ARV-393.
- 🚪
Significant equity dilution (>20%) without clear, positive corresponding pipeline milestones.
Unlock ARVN Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Arvinas Inc (ARVN) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
430
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Visit Arvinas Inc WebsiteInvestment Thesis
Arvinas presents an aggressive, high-risk, high-reward investment opportunity in its pioneering PROTAC protein degradation platform, which holds significant potential to revolutionize oncology. Despite recent uncertainties regarding the vepdegestrant partnership and a lack of transparent financial data, the company's robust pipeline, featuring multiple clinical-stage assets with promising early results, positions it for substantial upside if critical clinical and commercialization milestones are successfully navigated and addressed.
Is ARVN Stock Undervalued?
Unlock the full AI analysis for ARVN
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ARVN Price Targets & Strategy
12-Month Target
$28.00
Bull Case
$50.00
Bear Case
$5.00
Valuation Basis
Based on successful resolution of vepdegestrant partnership, positive Phase 1/2 data for pipeline assets, and sustained progress of the PROTAC platform, leading to a re-rating towards previous biotech highs for innovative platforms.
Entry Strategy
Dollar-cost average on dips below $10.00, or initiate position upon clear positive resolution of the vepdegestrant partnership or compelling ARV-806 data readouts.
Exit Strategy
Take initial profits at $25.00-$30.00; consider full exit if lead asset partnership fails or major clinical setbacks occur. Stop loss at $7.00.
Portfolio Allocation
5-10% for aggressive risk tolerance, given the highly speculative nature and early stage of commercialization for its lead assets.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ARVN Financially Healthy?
Valuation
P/E Ratio
-7.28
Profitability
Operating Margin
-31.52%
Net Margin
-19.47%
Return on Equity
-12.23%
EPS
$-1.00
Balance Sheet
Current Ratio
5.64
Quick Ratio
5.53
Debt/Equity
0.02
Cash Flow
EBITDA
-$113.80M
Does ARVN Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The PROTAC platform represents a novel and sophisticated approach to drug discovery, offering a lead in a potentially transformative field. Its durability depends on continued clinical success, effective patent protection, and the company's ability to innovate ahead of emerging competition in the protein degradation space.
Moat Erosion Risks
- •Intense competition in the protein degradation space from other biotechs and large pharmaceutical companies.
- •Failure of lead candidates in clinical trials, undermining platform validation.
- •Patent challenges or expiry reducing the exclusivity of their technology.
ARVN Competitive Moat Analysis
Sign up to see competitive advantages
ARVN Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Undetermined (No specific data provided to indicate retail sentiment trend)
Institutional Sentiment
Negative (Vanguard divested 100% of its holdings due to internal realignment effective 01/12/2026). No analyst ratings available.
Insider Activity (Form 4)
Noah Berkowitz (insider) sold 5,685 shares for $67,594.65 on 02/13/2026. Additionally, 6,022 vested RSUs were settled on 03/18/2026 (no sale value specified).
Options Flow
Normal options activity (No specific unusual options activity data provided in intelligence).
Earnings Intelligence
Next Earnings
Undetermined (No consensus EPS/revenue estimates or expected date available)
Surprise Probability
Undetermined (Due to lack of estimates and historical data)
Historical Earnings Pattern
Undetermined (No historical earnings reaction patterns available)
Key Metrics to Watch
Competitive Position
Top Competitor
No specific best-in-class competitor identified in the provided intelligence.
Market Share Trend
Undetermined (Company is in early clinical stages with no commercialized products to assess market share).
Valuation vs Peers
Cannot be assessed due to lack of reported valuation metrics (P/E, EV/EBITDA, P/S) for Arvinas.
Competitive Advantages
- •Proprietary PROTAC protein degradation platform (novel mechanism of action)
- •Multiple clinical-stage assets in oncology pipeline
- •Potential to overcome resistance to existing therapies
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ARVN Stock Higher?
Near-Term (0-6 months)
- •Resolution of vepdegestrant partnership by early June PDUFA (could be positive or negative catalyst)
- •Near-term Phase 1 data readouts for ARV-102, ARV-806, ARV-393 (from Leerink presentation)
- •ARV-806 (KRAS G12D) data expected from fully enrolled trial (before 2025 year-end guidance, so imminent)
Medium-Term (6-18 months)
- •Progression of pipeline assets (e.g., ARV-806) into later-stage clinical trials
- •Potential new strategic partnerships for other pipeline assets or platform licensing
- •Further validation of the PROTAC platform in additional disease areas
Long-Term (18+ months)
- •Commercialization of vepdegestrant (ARV-471) following regulatory approval and new partnership
- •Establishment of Arvinas as a market leader in protein degradation therapies
- •Pipeline diversification into non-oncology indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ARVN?
- ✓
Successful resolution and terms of the new vepdegestrant (ARV-471) partnership.
- ✓
Positive and durable clinical data readouts for ARV-806 (KRAS G12D) and ARV-393.
- ✓
Improved transparency and positive trends in financial health (cash runway, burn rate).
Bull Case Analysis
See what could go right with Premium
Competing with ARVN
See how Arvinas Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Arvinas Inc ARVN | — | 5.2 | -7.3 | $372.8M | -19.5% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $154.6B | 0.2 | 19.9 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Arvinas Inc (ARVN)?
As of April 4, 2026, Arvinas Inc has a DVR Score of 5.2 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Arvinas Inc use?
ARVN is the ticker symbol for Arvinas Inc. The company trades on the NMS.
What is the risk level for ARVN stock?
Our analysis rates Arvinas Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ARVN?
Arvinas Inc currently has a price-to-earnings (P/E) ratio of -7.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Arvinas Inc's revenue growing?
Arvinas Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is ARVN stock profitable?
Arvinas Inc has a profit margin of -19.5%. The company is currently unprofitable.
How often is the ARVN DVR analysis updated?
Our AI-powered analysis of Arvinas Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 4, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ARVN (Arvinas Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.